These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 29307196)

  • 1. Emilia: use cunning to survive cancer.
    Gligorov J; Richard S; Pivot X
    Chin Clin Oncol; 2018 Feb; 7(1):5. PubMed ID: 29307196
    [No Abstract]   [Full Text] [Related]  

  • 2. NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer.
    Elsada A; Doss S; Robertson J; Adam EJ
    Lancet Oncol; 2016 Feb; 17(2):143-144. PubMed ID: 26703893
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
    Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
    Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab emtansine for HER2-positive breast cancer.
    Venkatesan P
    Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
    Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 testing in patients with breast cancer.
    Dixon JM; Wilson V; Verrill M; Symmans WF
    BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
    [No Abstract]   [Full Text] [Related]  

  • 7. [New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated].
    Bonnemort J; Bellesoeur A
    Bull Cancer; 2021; 108(7-8):673-675. PubMed ID: 34172272
    [No Abstract]   [Full Text] [Related]  

  • 8. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant capecitabine for HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2017 Jul; 18(7):e375. PubMed ID: 28602775
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
    Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
    Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment combinations for HER2-positive breast cancer.
    Pegram M
    Oncology (Williston Park); 2013 Apr; 27(4):258, 260. PubMed ID: 23781688
    [No Abstract]   [Full Text] [Related]  

  • 14. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
    Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
    Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
    Goel S; Winer EP
    Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058
    [No Abstract]   [Full Text] [Related]  

  • 16. Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?
    Altundag K
    J BUON; 2017; 22(1):281-282. PubMed ID: 28365969
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer.
    Luen SJ; Loi S
    Chin Clin Oncol; 2018 Feb; 7(1):2. PubMed ID: 29156891
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.